Thadhani, RaviPowe, CamilleTjoa, May LeeKhankin, EliyahuYe, JunEcker, JeffreySchneyer, AlanKarumanchi, Subbian2012-02-142009Thadhani, Ravi, Camille E. Powe, May Lee Tjoa, Eliyahu Khankin, Jun Ye, Jeffrey Ecker, Alan Schneyer, and S. Ananth Karumanchi. 2010. First-Trimester Follistatin-Like-3 Levels in Pregnancies Complicated by Subsequent Gestational Diabetes Mellitus. Diabetes Care 33(3): 664-669.0149-5992http://nrs.harvard.edu/urn-3:HUL.InstRepos:8160880Objective: To determine whether maternal levels of follistatin-like-3 (FSTL3), an inhibitor of activin and myostatin involved in glucose homeostasis, are altered in the first trimester of pregnancies complicated by subsequent gestational diabetes mellitus (GDM). Research Design and Methods: This was a nested case-control study of subjects enrolled in a prospective cohort of pregnant women with and without GDM (\(\geq\)2 abnormal values on a 100-g glucose tolerance test at ~28 weeks of gestation). We measured FSTL3 levels in serum collected during the first trimester of pregnancy. Logistic regression analyses were used to determine the risk of GDM. Results: Women who developed GDM (n = 37) had lower first-trimester serum levels of FSTL3 compared with women who did not (n = 127) (median 10,789 [interquartile range 7,013-18,939] vs. 30,670 [18,370-55,484] pg/ml, P < 0.001). When subjects were divided into tertiles based on FSTL3 levels, women with the lowest levels demonstrated a marked increase in risk for developing GDM in univariate (odds ratio 11.2 [95% CI 3.6-35.3]) and multivariate (14.0 [4.1-47.9]) analyses. There was a significant negative correlation between first-trimester FSTL3 levels and ~28-week nonfasting glucose levels (r = -0.30, P < 0.001). Conclusions: First-trimester FSTL3 levels are associated with glucose intolerance and GDM later in pregnancy.en-UScardiovascular and metabolic riskJournal Article2012-02-1410.2337/dc09-1745